Edition:
United Kingdom

Emergent BioSolutions Inc (EBS.N)

EBS.N on New York Stock Exchange

60.65USD
7:57pm BST
Change (% chg)

$-0.52 (-0.86%)
Prev Close
$61.18
Open
$60.07
Day's High
$60.65
Day's Low
$58.90
Volume
28,712
Avg. Vol
129,058
52-wk High
$67.11
52-wk Low
$36.55

Chart for

About

Emergent BioSolutions Inc. is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical... (more)

Overall

Beta: 1.27
Market Cap(Mil.): $1,669.07
Shares Outstanding(Mil.): 41.21
Dividend: --
Yield (%): --

Financials

  EBS.N Industry Sector
P/E (TTM): 29.50 30.90 33.64
EPS (TTM): 1.37 -- --
ROI: 7.33 14.75 14.27
ROE: 10.48 16.25 15.99

Emergent BioSolutions to buy Narcan maker Adapt Pharma

Emergent BioSolutions Inc said on Tuesday it would buy privately held Adapt Pharma, beefing up its portfolio with Narcan, the only FDA approved needle-free emergency opioid overdose treatment.

28 Aug 2018

UPDATE 2-Emergent BioSolutions to buy Narcan maker Adapt Pharma

* Adapt partner Opiant soars in after-hours trading (Adds details and comment from conference call)

28 Aug 2018

Emergent BioSolutions to buy Adapt Pharma for up to $735 mln

Aug 28 Emergent BioSolutions Inc said on Tuesday it would buy privately held Adapt Pharma for up to $735 million to acquire its drug Narcan, the only needle-free emergency treatment approved to treat opioid overdose.

28 Aug 2018

BRIEF-Emergent BioSolutions Reports Q1 Adjusted Loss Per Share $0.03

* EMERGENT BIOSOLUTIONS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

03 May 2018

Earnings vs. Estimates